|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
40 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
102-12 NCT00090038
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 to 120
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
MO19872 NCT00430352
|
|
|
|
|
|
|
|
Last Modified: 8/26/2004  First Published: 7/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
UCLA-0302013 CHIR-IL2NHL03-A01, NCT00066534
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
20 to 69
|
|
|
|
Other
|
|
|
|
JCOG0203 C000000033, NCT00147121
|
|
|
|
|
|
|
|
Last Modified: 8/2/2007  First Published: 1/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
60 and over
|
|
|
|
NCI
|
|
|
|
ECOG-E4494 E4494, CLB-9793, SWOG-E4494, NCT00003150
|
|
|
|
|
|
|
|
Last Modified: 8/15/2007  First Published: 3/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
E-1496 CLB-59902, NCT00003204, E1496
|
|
|
|
|
|
|
|
Last Modified: 2/27/2007  First Published: 5/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
|
|
|
|
SWS-SAKK-35/98 ICR-35/98, EU-98009, NCT00003280
|
|
|
|
|
|
|
|
Last Modified: 12/1/1999  First Published: 7/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Not specified
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
IDEC-106-04 MAYO-977802
|
|
|
|
|
|
|
|
Last Modified: 5/25/2007  First Published: 12/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
Over 18
|
|
|
|
NCI
|
|
|
|
AMC-010 CPMC-IRB-9691, CWRU-AMC-1400, UCLA-9810029, NCT00003595
|
|
|
|
|
|
|
|
Last Modified: 12/1/1999  First Published: 4/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
IDEC-106-06 MAYO-987804, UCLA-9808026
|
|
|
|